Share this article
Share this article
to reach USD 45.4 billion by
2028, according to a new report by Grand View Research, Inc. It is expected
to expand at a CAGR of 22.3% from 2021 to 2028. Increasing funding, investments in research and development, and successful product launches are boosting the market growth.
Key suggestions from the report:
By phase, the phase II segment held the largest share of over 50.0% in 2020 owing to the large number of therapies currently in development in phase II
Based on indication, the oncology segment held the largest share of 47.0% in 2020 as oncology alone contributed to 600 CGT clinical trials out of around 1,000
Cell And Gene Therapy Clinical Trials Market Size Worth $45 4 Billion By 2028: Grand View Research, Inc
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
GSK expands its clinical trial manufacturing capacity at dedicated CGT facility in UK Cell and Gene Therapy Catapult (CGT Catapult) says that GSK will leverage its Stevenage facility to perform GMP cell processing and accelerate its cell and gene therapy pipeline for clinical trials.
Through this agreement, GSK is looking to improve its GMP cell processing network to advance its early stage pipeline and streamline technical transfer.
“The move by a leading pharmaceutical company like GSK to establish ATMP manufacturing capabilities at the CGT Catapult facility in Stevenage highlights the UK’s globally leading position for large and smaller organizations alike to develop, manufacture and deliver cell and gene therapies,” said Matthew Durdy, CEO, CGT Catapult.
GSK to leverage the Cell and Gene Therapy Catapult’s facility in Stevenage
11th March 2021
GlaxoSmithKline (GSK) is set to leverage the Cell and Gene Therapy (CGT) Catapult’s facility in Stevenage to expand its own clinical trial manufacturing capacity for cell and gene therapy.
GSK will use the Stevenage facility to perform GMP cell processing to accelerate its pipeline of cell and gene therapy for clinical trials and streamline technical transfer.
“The UK already has significant capabilities in cell and gene therapy, and this agreement illustrates how strategic investments by GSK can make them even stronger,” said Tony Wood, senior vice president, medicinal science and technology, GSK.
WuXi AppTec acquires UK gene therapy company Oxgene WuXi AppTec has completed its acquisition of Oxgene, a UK contract research and development organization that designs and develops scalable gene therapy technologies.
Oxgene – which will retain its name – will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU): which is Shanghai-headquartered Wuxi AppTech’s cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) business unit.
It will be the unit’s first facility in Europe.
Scaling up tech
Oxford biotech Oxgene was founded in 2011. It offers discovery and biomanufacturing solutions to the cell and gene therapy industries through novel technologies and contract research solutions; as well as manufacturing systems. Its novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing are designed to simplify cell and gene therapy
vimarsana © 2020. All Rights Reserved.